Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Cincinnati Comprehensive Mental Health Agency helping people through many services and a staff of more than 500 highly skilled professionals.
FREE developmental screening! Tampa, St. Petersburg, Wesley Chapel clinic and school based pediatric therapy services. Physical, Occupational, Speech, Applied Behavioral Analysis
Midwest Eye Consultants provides total eye care from eye health exams to the treatment of eye diseases. See our locations page to find an office near you.
The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.